[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490676":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":42,"locations":46,"responsibleParty":51,"collaborators":46,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":46,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":46,"enrollmentInfo":62,"targetDuration":46,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":76,"whyStopped":46,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":46},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"FAST Guided Strategy (μQFR+RWS)","EXPERIMENTAL","1. μQFR is measured in all non-infarct related arteries containing any non-culprit lesion with visually-assessed DS% ≥50% and ≤90% with RVD ≥2.5 mm.\n\n   1. μQFR ≤0.80: PCI\n   2. RWS ≥13%: PCI\n   3. μQFR \\>0.80 and RWS \\\u003C13%: Deferral\n   4. DS% \\>90%: PCI without the need of μQFR or RWS\n2. For all patients undergoing PCI, post-PCI μQFR measurement is recommended; if μQFR \\\u003C0.90, if the reason is obvious post-dilation with a non-compliant balloon or bail-out stenting should be considered; if the reason is not obvious intravascular imaging should be considered.",[13,14],"Diagnostic Test: FAST Technique","Diagnostic Test: Angiography",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard Treatment Strategy","SHAM_COMPARATOR","1. PCI should be performed of all non-culprit lesions with visual DS% ≥70% in all non-infarct related arteries with RVD ≥2.5 mm;\n2. For a non-culprit lesion with visually DS% 50-70%, PCI can be performed if FFR ≤0.80 or iFR ≤0.89.",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIAGNOSTIC_TEST","FAST Technique","The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.",[9],[27],"The next-generation quantitative flow ratio and radial wall strain",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Angiography","Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.",[9,16],[33],"Coronary angiography",[35,39],{"name":36,"affiliation":37,"role":38},"Bo Xu, MBBS","Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, Shenzhen","PRINCIPAL_INVESTIGATOR",{"name":40,"affiliation":41,"role":38},"Lei Song, MD","Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing",[43,48],{"name":36,"role":44,"phone":45,"phoneExt":46,"email":47},"CONTACT","+86-10-88322562",null,"bxu@citmd.com",{"name":40,"role":44,"phone":49,"phoneExt":46,"email":50},"+86-13241310112","drsong@vip.163.com",{"type":52,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR","100490676","the-favor-v-ami-trial-100490676",false,"NCT05669222","The FAVOR V AMI Trial","Functional and Angiography-Derived Strain Guided Multi-Vessel\u002FLesion Revascularization Strategy in Patients With Acute ST-Segment Elevation Myocardial Infarction (FAVOR V AMI)","Inclusion Criteria:\n\n* General inclusion\n\n  1. Age ≥18 years\n  2. STEMI ≤30d\n  3. Successful primary PCI of all culprit lesion(s) responsible for the STEMI (visually-assessed residual stenosis \\\u003C30% in stent-treated lesions or \\\u003C50% in DCB-treated or PTCA-treated lesions, with TIMI-3 flow in all treated vessels)\n  4. No MACE event between the index PCI and the staged randomized procedure\n  5. Able to understand the trial design and provide written informed consent\n* Angiographic inclusion:\n\n  1. The presence of at least 1 non-culprit lesion with DS% 50%-90% in any non-infarct related artery with RVD ≥2.5 mm by visual assessment\n  2. Non-culprit lesions are potentially eligible for PCI Note: All lesions in the infarct related arteries with DS ≥70% and RVD ≥2.5 mm by visual assessment must be successfully treated either during the index primary PCI or the staged procedure prior to randomization Note: There may also be 1 or more NCL with DS% \\>90% (including a CTO) as long as there is at least 1 NCL with DS% 50%-90% as above. Any such lesions in which PCI is intended must be treated successfully either during the index primary PCI or the staged procedure prior to randomization.\n\nExclusion Criteria:\n\n* General exclusion\n\n  1. Cardiogenic shock or refractory hypotension (Killip IV)\n  2. On pressors or use of or need for intra-aortic balloon pump or other mechanical circulatory support devices\n  3. Intubated\n  4. Prior thrombolytic therapy for this admission\n  5. Cockcroft-Gault-calculated CrCl \\\u003C30 ml\u002Fkg\n  6. Pregnant or woman of child-bearing potential\n  7. Life expectancy less than 1 year for non-cardiac causes\n  8. Allergy to iodine-containing contrast agents which cannot be adequately premedicated\n  9. Unable to tolerate DAPT for at least 6 months\n  10. Prior CABG or planned CABG\n  11. Any planned surgery within 6 months\n  12. Any condition that may interfere with any follow-up procedures (e.g. dementia, drug use)\n* Angiographic exclusion\n\n  1. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification, branch ostium cannot be shown clearly, severe overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to μQFR or RWS measurement\n  2. Unable to judge culprit lesion or infarct-related artery according to current evidence","ALL","18 Years",{"count":63,"type":64},5000,"ESTIMATED","INTERVENTIONAL",[67],"NA","The FAVOR V AMI study is a prospective, multicenter, blinded, randomized, sham-controlled trial comparing the long-term clinical outcomes of the \"Functional and Angiography-derived Strain inTegration (FAST)\" technique (next-generation quantitative flow ratio \\[μQFR\\] and radial wall strain \\[RWS\\]) guided percutaneous coronary intervention (PCI) strategy, with standard treatment strategy, in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD).",[70,71,72],"ST-Segment Elevation Myocardial Infarction","Multivessel Coronary Artery Disease","Percutaneous Coronary Intervention",[74,70,71,72,75],"Quantitative Flow Ratio","Radial Wall Strain","NOT_YET_RECRUITING","2023-09-10",{"date":79,"type":80},"2023-09-13","ACTUAL",{"date":82,"type":64},"2023-09-30",{"date":84,"type":64},"2028-06",{"name":5,"class":6}]